Madhava Balakrishna Mallia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madhava Balakrishna Mallia has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Anupam Mathur
Radiopharmaceuticals Program Board of Radiation and Isotope Technology Navi Mumbai India
4 shared publications Ashutosh Dash
Homi Bhabha National Institute (HBNI), Mumbai, India
4 shared publicationsSweety Mittal
Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
4 shared publicationsViju Chirayil
Radiopharmaceuticals Division Bhabha Atomic Research Centre, Trombay Mumbai India
4 shared publicationsChandan Kumar
Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
3 shared publications- Hal Dhar Sarma
Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai-400085, India
3 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 69 (3) , e70025
Synthesis, Radiochemical Characterization, and Biodistribution of a 188 Re Analogue of [ 131 I]mIBG in a Neuroblastoma Xenograft Model
[ 131 I]meta‐iodobenzylguanidine (mIBG) in variable dosage forms is widely used for the therapy of neuroendocrine tumors. Our group previously reported a 99m Tc analogue of [ 131 I]mIBG that demonstrated high specificity in vitro towards norepinephrine transporter (NET)–positive neuroblastoma cells. Considering that the 99m Tc/ 188 Re pair serves as a useful theranostic combination, we herein describe the synthesis of its 188 Re analogue and evaluate its potential for therapeutic applications. A benzylguanidine derivative functionalized at the meta position via an isonitrile moiety (“ 1 ”) was employed for 188 Re complexation following Re‐“4 + 1” chemistry. Synthesized 188 Re complex 6 was evaluated in NET‐positive SK‐N‐SH neuroblastoma cells and corresponding xenograft models. Cellular uptake studies revealed that the 188 Re complex 6 exhibited ~50% of the uptake observed for [ 125 I]mIBG. Nonetheless, it retained significant NET specificity (~60%), as confirmed by inhibition experiments using desmethylimipramine (DMI). Biodistribution studies in SK‐N‐SH xenograft‐bearing mice demonstrated tumor uptake of 4.07 ± 0.08%ID/g at 30 min ( p > 0.05), with significant retention up to 3 h (4.99 ± 0.08%ID/g). Tumor uptake was shown to be NET‐specific, as pre‐treatment with excess DMI significantly inhibited tracer accumulation in vivo. Bioevaluation of the synthesized 188 Re complex 6 confirmed its affinity for NETs; however, limited in vivo stability restricted its suitability for therapeutic application.
- 17 March 2026
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 69 (3) , e70025
Open AccessSynthesis, Radiochemical Characterization, and Biodistribution of a 188 Re Analogue of [ 131 I]mIBG in a Neuroblastoma Xenograft Model
[ 131 I]meta‐iodobenzylguanidine (mIBG) in variable dosage forms is widely used for the therapy of neuroendocrine tumors. Our group previously reported a 99m Tc analogue of [ 131 I]mIBG that demonstrated high specificity in vitro towards norepinephrine transporter (NET)–positive neuroblastoma cells. Considering that the 99m Tc/ 188 Re pair serves as a useful theranostic combination, we herein describe the synthesis of its 188 Re analogue and evaluate its potential for therapeutic applications. A benzylguanidine derivative functionalized at the meta position via an isonitrile moiety (“ 1 ”) was employed for 188 Re complexation following Re‐“4 + 1” chemistry. Synthesized 188 Re complex 6 was evaluated in NET‐positive SK‐N‐SH neuroblastoma cells and corresponding xenograft models. Cellular uptake studies revealed that the 188 Re complex 6 exhibited ~50% of the uptake observed for [ 125 I]mIBG. Nonetheless, it retained significant NET specificity (~60%), as confirmed by inhibition experiments using desmethylimipramine (DMI). Biodistribution studies in SK‐N‐SH xenograft‐bearing mice demonstrated tumor uptake of 4.07 ± 0.08%ID/g at 30 min ( p > 0.05), with significant retention up to 3 h (4.99 ± 0.08%ID/g). Tumor uptake was shown to be NET‐specific, as pre‐treatment with excess DMI significantly inhibited tracer accumulation in vivo. Bioevaluation of the synthesized 188 Re complex 6 confirmed its affinity for NETs; however, limited in vivo stability restricted its suitability for therapeutic application.
- Open Access
- 15 January 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (1) , e70228
Exploring CPP Enhanced Hypoxia Targeting: An Approach Using Radiolabeled 2‐nitroimidazole TAT Conjugate
Mediated by their protein transduction domain, cell‐penetrating peptides (CPPs) have been widely explored for facilitating intracellular delivery of drugs and small molecules. In this study, a radiolabeled, 2‐nitroimidazole conjugated TAT (TAT ‐ transactivator of transcription) peptide was prepared and evaluated for targeting tumor hypoxia. The conjugate was radiolabeled with iodine‐125 and comprehensive in vitro and in vivo evaluations were conducted to assess its potential to target hypoxic cells. A radiolabeled [ 125 I]I‐TAT was also prepared as a control. In vitro studies carried out in CHO cells under hypoxic conditions revealed three fold uptake of [ 125 I]I‐TAT‐2‐NIM compared to [ 125 I]I‐TAT at 1 h post‐incubation, which further increased sixfold at 4 h post‐incubation, clearly demonstrating the role of nitroimidazole in targeting hypoxic cells. However, the study also revealed a negative influence of hypoxia in cellular uptake, wherein the radiolabeled TAT peptides showed a lower uptake in cells under hypoxic conditions than in normoxic conditions. In vivo, [ 125 I]I‐TAT‐2‐NIM showed uptake and retention in the tumor with the tumor/muscle ratio above 2 at all time points studied. However, the tumor/blood ratio was found to decrease with time. Though [ 12 5 I]I‐TAT‐2‐NIM showed higher accumulation in hypoxic cells compared to [ 125 I]I‐TAT in vitro, the negative influence of hypoxia on the cellular uptake of TAT‐peptides possibly indicates their limitation for hypoxia targeting applications.
- 15 January 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (1) , e70228
Open AccessExploring CPP Enhanced Hypoxia Targeting: An Approach Using Radiolabeled 2‐nitroimidazole TAT Conjugate
Mediated by their protein transduction domain, cell‐penetrating peptides (CPPs) have been widely explored for facilitating intracellular delivery of drugs and small molecules. In this study, a radiolabeled, 2‐nitroimidazole conjugated TAT (TAT ‐ transactivator of transcription) peptide was prepared and evaluated for targeting tumor hypoxia. The conjugate was radiolabeled with iodine‐125 and comprehensive in vitro and in vivo evaluations were conducted to assess its potential to target hypoxic cells. A radiolabeled [ 125 I]I‐TAT was also prepared as a control. In vitro studies carried out in CHO cells under hypoxic conditions revealed three fold uptake of [ 125 I]I‐TAT‐2‐NIM compared to [ 125 I]I‐TAT at 1 h post‐incubation, which further increased sixfold at 4 h post‐incubation, clearly demonstrating the role of nitroimidazole in targeting hypoxic cells. However, the study also revealed a negative influence of hypoxia in cellular uptake, wherein the radiolabeled TAT peptides showed a lower uptake in cells under hypoxic conditions than in normoxic conditions. In vivo, [ 125 I]I‐TAT‐2‐NIM showed uptake and retention in the tumor with the tumor/muscle ratio above 2 at all time points studied. However, the tumor/blood ratio was found to decrease with time. Though [ 12 5 I]I‐TAT‐2‐NIM showed higher accumulation in hypoxic cells compared to [ 125 I]I‐TAT in vitro, the negative influence of hypoxia on the cellular uptake of TAT‐peptides possibly indicates their limitation for hypoxia targeting applications.
- Open Access
- 4 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (29) , 23943-23953
Convenient one-pot synthesis of 1-(4-(4-(2-[ 18 F]fluoroethoxy)phenyl)piperazin-1-yl)ethanone ([ 18 F]FEt-PPZ) for imaging tumors expressing sigma-1 receptors
Development of a sigma-1 receptor (σ1R) targeting PET-radiopharmaceutical from commercial source using in silico methods.
- 4 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (29) , 23943-23953
Open AccessConvenient one-pot synthesis of 1-(4-(4-(2-[ 18 F]fluoroethoxy)phenyl)piperazin-1-yl)ethanone ([ 18 F]FEt-PPZ) for imaging tumors expressing sigma-1 receptors
Development of a sigma-1 receptor (σ1R) targeting PET-radiopharmaceutical from commercial source using in silico methods.
- 16 June 2025
- Published by Walter de Gruyter GmbH in Radiochimica Acta
Synthesis and radiolabelling studies of hynic conjugated PSMA targeting ligands
Development and clinical translation of small molecule PSMA-ligands labelled with a SPECT-radioisotope such as technetium-99m (99mTc) has immense importance, particularly in countries with high population density and limited amenities. Towards this, herein we report the total chemical synthesis of five Hynic (2-hydrazinonicotinic acid) conjugated PSMA ligands employing the solution phase alloc chemistry. A linear synthetic strategy was adopted for the construction of all target molecules. The amino acids that act as spacers were synthesized from corresponding unprotected precursors in 60–65 % overall yield. All the synthesized ligands were appropriately characterized using NMR, HPLC, and MS, to confirm their structural veracity. After the successful synthesis, all the ligands were radiolabelled using 99mTc and the extent of 99mTc radiolabelling was established using radioHPLC and radioTLC analysis. Two among the five ligands displayed radiochemical purity >90 %, adequate for diagnostic applications.
- 16 June 2025
- Published by Walter de Gruyter GmbH in Radiochimica Acta
Synthesis and radiolabelling studies of hynic conjugated PSMA targeting ligands
Development and clinical translation of small molecule PSMA-ligands labelled with a SPECT-radioisotope such as technetium-99m (99mTc) has immense importance, particularly in countries with high population density and limited amenities. Towards this, herein we report the total chemical synthesis of five Hynic (2-hydrazinonicotinic acid) conjugated PSMA ligands employing the solution phase alloc chemistry. A linear synthetic strategy was adopted for the construction of all target molecules. The amino acids that act as spacers were synthesized from corresponding unprotected precursors in 60–65 % overall yield. All the synthesized ligands were appropriately characterized using NMR, HPLC, and MS, to confirm their structural veracity. After the successful synthesis, all the ligands were radiolabelled using 99mTc and the extent of 99mTc radiolabelling was established using radioHPLC and radioTLC analysis. Two among the five ligands displayed radiochemical purity >90 %, adequate for diagnostic applications.
- Open Access
- 10 September 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (6) , e22258
A thiourea‐bridged 99mTc(CO)3‐dipicolylamine‐2‐nitroimidazole complex for targeting tumor hypoxia: Utilizing metabolizable thiourea‐bridge to improve pharmacokinetics
The 2‐nitroimidazole based 99mTc‐radiopharmaceuticals are widely explored for imaging tumor hypoxia. Radiopharmaceuticals for targeting hypoxia are often lipophilic and therefore, show significant uptake in liver and other vital organs. In this context, lipophilic radiopharmaceuticals with design features enabling faster clearance from liver may be more desirable. A dipicolylamine‐NCS bifunctional chelator that could generate a thiourea‐bridge up on conjugation to primary amine bearing molecule was used to synthesize a 2‐nitroimidazole‐dipicolyl amine ligand for radiolabeling with 99mTc(CO)3 core. Corresponding Re(CO)3‐analogue was prepared to establish the structure of 2‐nitroimidazole‐99mTc(CO)3 complex prepared in trace level. The 2‐nitroimidazole‐99mTc(CO)3 complex showed a hypoxic to normoxic ratio of ~2.5 in CHO cells at 3 h. In vivo, the complex showed accumulation and retention in tumor with high tumor to blood and tumor to muscle ratio. The study demonstrated the utility of metabolizable thiourea‐bridge in 2‐nitroimidazole‐99mTc(CO)3 complex in inducing faster clearance of the radiotracer from liver. The dipicolylamine‐NCS bifunctional chelator reported herein can also be used for radiolabeling other class of target specific molecules with 99mTc(CO)3 core.
- 10 September 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (6) , e22258
Open AccessA thiourea‐bridged 99mTc(CO)3‐dipicolylamine‐2‐nitroimidazole complex for targeting tumor hypoxia: Utilizing metabolizable thiourea‐bridge to improve pharmacokinetics
The 2‐nitroimidazole based 99mTc‐radiopharmaceuticals are widely explored for imaging tumor hypoxia. Radiopharmaceuticals for targeting hypoxia are often lipophilic and therefore, show significant uptake in liver and other vital organs. In this context, lipophilic radiopharmaceuticals with design features enabling faster clearance from liver may be more desirable. A dipicolylamine‐NCS bifunctional chelator that could generate a thiourea‐bridge up on conjugation to primary amine bearing molecule was used to synthesize a 2‐nitroimidazole‐dipicolyl amine ligand for radiolabeling with 99mTc(CO)3 core. Corresponding Re(CO)3‐analogue was prepared to establish the structure of 2‐nitroimidazole‐99mTc(CO)3 complex prepared in trace level. The 2‐nitroimidazole‐99mTc(CO)3 complex showed a hypoxic to normoxic ratio of ~2.5 in CHO cells at 3 h. In vivo, the complex showed accumulation and retention in tumor with high tumor to blood and tumor to muscle ratio. The study demonstrated the utility of metabolizable thiourea‐bridge in 2‐nitroimidazole‐99mTc(CO)3 complex in inducing faster clearance of the radiotracer from liver. The dipicolylamine‐NCS bifunctional chelator reported herein can also be used for radiolabeling other class of target specific molecules with 99mTc(CO)3 core.
- Open Access
- 20 December 2023
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 5 (2) , 513-520
Re-engineered theranostic gold nanoparticles for targeting tumor hypoxia
Developing nanovehicles for selective delivery of a radiation dose/drug to hypoxic tumors is a present-day clinical requirement for effective treatment of cancer. Herein, we describe our attempt to re-engineer the earlier reported lipoic acid-capped 177Lu-labeled nitroimidazole-decorated gold nanoparticles to favorably modulate their pharmacokinetics to reduce uptake in the reticuloendothelial system while retaining the uptake in tumors. Towards this, gold nanoparticles with PEG-chains terminated with 2-nitroimidazole and Bz-DOTA were synthesized [(DOTA)AuNP-PEG-2K-(2-NIM)]. Surface modification of the gold nanoparticles with PEG-2K and 2-nitroimidazole was confirmed through infrared spectroscopy. The conjugation of Bz-DOTA on the nanoparticle surface was confirmed by UV-Vis spectroscopy, which showed a peak at 260–280 nm corresponding to Bz-DOTA. The DLS analysis of gold nanoparticles showed an effective hydrodynamic diameter of 28.9 ± 1.50 nm with a zeta potential value of −20.62 ± 0.05 mV at pH 7.4. The nanoparticles were radiolabeled with lutetium-177 with >98% radiochemical purity. In vitro studies using radiolabeled nanoparticles ([177Lu]Lu-(DOTA)AuNP-PEG-2K-(2-NIM)) in CHO cells showed their 2-fold uptake under hypoxic conditions (at 4 h post incubation) compared to the radiolabeled nanoparticles without nitroimidazole units. The hypoxia selective uptake of the nanoparticles was further confirmed by flow cytometry using a fluorescent analogue (DOTA)AuNP-PEG-2K-(2-NIM)(FITC). It was, however, observed that hypoxic cell uptake of the PEG-2K capped nanoparticles was lower than that of their lipoic acid capped counterpart. In vivo biodistribution studies in tumor bearing Swiss mice demonstrated that PEGylation of nanoparticles could significantly reduce the uptake in the RES while retaining uptake in tumors albeit to a lesser extent.
- 20 December 2023
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 5 (2) , 513-520
Open AccessRe-engineered theranostic gold nanoparticles for targeting tumor hypoxia
Developing nanovehicles for selective delivery of a radiation dose/drug to hypoxic tumors is a present-day clinical requirement for effective treatment of cancer. Herein, we describe our attempt to re-engineer the earlier reported lipoic acid-capped 177Lu-labeled nitroimidazole-decorated gold nanoparticles to favorably modulate their pharmacokinetics to reduce uptake in the reticuloendothelial system while retaining the uptake in tumors. Towards this, gold nanoparticles with PEG-chains terminated with 2-nitroimidazole and Bz-DOTA were synthesized [(DOTA)AuNP-PEG-2K-(2-NIM)]. Surface modification of the gold nanoparticles with PEG-2K and 2-nitroimidazole was confirmed through infrared spectroscopy. The conjugation of Bz-DOTA on the nanoparticle surface was confirmed by UV-Vis spectroscopy, which showed a peak at 260–280 nm corresponding to Bz-DOTA. The DLS analysis of gold nanoparticles showed an effective hydrodynamic diameter of 28.9 ± 1.50 nm with a zeta potential value of −20.62 ± 0.05 mV at pH 7.4. The nanoparticles were radiolabeled with lutetium-177 with >98% radiochemical purity. In vitro studies using radiolabeled nanoparticles ([177Lu]Lu-(DOTA)AuNP-PEG-2K-(2-NIM)) in CHO cells showed their 2-fold uptake under hypoxic conditions (at 4 h post incubation) compared to the radiolabeled nanoparticles without nitroimidazole units. The hypoxia selective uptake of the nanoparticles was further confirmed by flow cytometry using a fluorescent analogue (DOTA)AuNP-PEG-2K-(2-NIM)(FITC). It was, however, observed that hypoxic cell uptake of the PEG-2K capped nanoparticles was lower than that of their lipoic acid capped counterpart. In vivo biodistribution studies in tumor bearing Swiss mice demonstrated that PEGylation of nanoparticles could significantly reduce the uptake in the RES while retaining uptake in tumors albeit to a lesser extent.
- 20 June 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 139
Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development
- 20 June 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 139
Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development
- 8 February 2022
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 37 (1) , 63-70
Preparation of Rhenium-188-Lipiodol Using Freeze-Dried Kits for Transarterial Radioembolization: An Overview and Experience in a Hospital Radiopharmacy
Background: Rhenium-188( 188 Re)-lipiodol is a clinically effective, economically viable radiopharmaceutical for Selective Internal Radiation Therapy of liver cancer. Present study evaluates the performance of three freeze-dried kits with respect to the radiochemistry, quality control, and overall “ease of preparation” aspects in a hospital radiopharmacy. Materials and Methods: Freeze-dried kits of acetylated 4-hexadecyl-4,7-diaza-1,10-decanedithiol (AHDD), super six sulfur (SSS), and diethyl dithiocarbamate (DEDC), obtained commercially or received as gift, were used for the preparation of 188 Re-lipiodol using freshly eluted 188 Re-sodium perrhenate from commercial Tungsten-188/ 188 Re generator following recommended procedures. Results: The overall yield of 188 Re-lipiodol prepared using AHDD Kit, SSS Kit, and DEDC Kit was 74.82% ± 3.3%, 87.55% ± 4.8%, and 76.38% ± 4.6%, respectively. Observed radiochemical purity (RCP) of 188 Re-lipiodol prepared using these kits was 88.65% ± 2.8%, 92.92% ± 3.0%, and 91.38% ± 3.0%, respectively. Using a modified version of the DEDC Kits, overall yield of 87.17% ± 2.7% and RCP of 95.43% ± 2.3% could be achieved. Conclusions: While all three freeze-dried kits can be used for the preparation of 188 Re-lipiodol in >70% overall yield, the modified version of DEDC Kits has some advantages in terms of preparation time and volume of Rhenium-188 activity that can be added to the kit vial. The latter feature of the DEDC Kit is particularly useful for patient dose preparation with 188 Re activity of low radioactive concentration.
- 8 February 2022
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 37 (1) , 63-70
Preparation of Rhenium-188-Lipiodol Using Freeze-Dried Kits for Transarterial Radioembolization: An Overview and Experience in a Hospital Radiopharmacy
Background: Rhenium-188( 188 Re)-lipiodol is a clinically effective, economically viable radiopharmaceutical for Selective Internal Radiation Therapy of liver cancer. Present study evaluates the performance of three freeze-dried kits with respect to the radiochemistry, quality control, and overall “ease of preparation” aspects in a hospital radiopharmacy. Materials and Methods: Freeze-dried kits of acetylated 4-hexadecyl-4,7-diaza-1,10-decanedithiol (AHDD), super six sulfur (SSS), and diethyl dithiocarbamate (DEDC), obtained commercially or received as gift, were used for the preparation of 188 Re-lipiodol using freshly eluted 188 Re-sodium perrhenate from commercial Tungsten-188/ 188 Re generator following recommended procedures. Results: The overall yield of 188 Re-lipiodol prepared using AHDD Kit, SSS Kit, and DEDC Kit was 74.82% ± 3.3%, 87.55% ± 4.8%, and 76.38% ± 4.6%, respectively. Observed radiochemical purity (RCP) of 188 Re-lipiodol prepared using these kits was 88.65% ± 2.8%, 92.92% ± 3.0%, and 91.38% ± 3.0%, respectively. Using a modified version of the DEDC Kits, overall yield of 87.17% ± 2.7% and RCP of 95.43% ± 2.3% could be achieved. Conclusions: While all three freeze-dried kits can be used for the preparation of 188 Re-lipiodol in >70% overall yield, the modified version of DEDC Kits has some advantages in terms of preparation time and volume of Rhenium-188 activity that can be added to the kit vial. The latter feature of the DEDC Kit is particularly useful for patient dose preparation with 188 Re activity of low radioactive concentration.
- Open Access
- 27 January 2022
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 3 (4) , 1993-1999
Hypoxia targeting lutetium-177-labeled nitroimidazole-decorated gold particles as cancer theranostic nanoplatforms
Theranostic 177Lu-labeled nitroimidazole-decorated gold nanoparticles showed ∼9-fold uptake in CHO cells under hypoxic conditions compared to normoxic conditions.
- 27 January 2022
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 3 (4) , 1993-1999
Open AccessHypoxia targeting lutetium-177-labeled nitroimidazole-decorated gold particles as cancer theranostic nanoplatforms
Theranostic 177Lu-labeled nitroimidazole-decorated gold nanoparticles showed ∼9-fold uptake in CHO cells under hypoxic conditions compared to normoxic conditions.
- 1 May 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 61-67
68Ga-labeled PET tracers for targeting tumor hypoxia: Role of bifunctional chelators on pharmacokinetics
- 1 May 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 61-67
68Ga-labeled PET tracers for targeting tumor hypoxia: Role of bifunctional chelators on pharmacokinetics